Atara reports FY 2025 net income of $32.7M; cash runway extended through YE 2026

Atara Biotherapeutics, Inc.

Net income of $32.7M ($2.61 per share) in FY 2025 vs. net loss of $85.4M in FY 2024.
Cash, equivalents and investments $8.5M at Dec 31, 2025; net cash used in ops $50.9M in FY 2025.
Operating expenses declined sharply; expects cash plus $3.0M ATM proceeds to fund ops through YE 2026.
Pierr Fabre scheduled FDA Type A meeting for tab-cel PTLD; regulatory update expected in Q2 2026.
Milestone payment of $9.0M due to HCRx deferred from June 2026 to Jan 2028; warrant issued for 400K shares.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Atara Biotherapeutics, Inc. reported the fiscal year ended December 31, 2025 results: revenue $120.8 million, net income $32.7 million, EPS $2.61 per share. Guidance initiated.

Period: the fiscal year ended December 31, 2025
Revenue: $120.8 million
Net income: $32.7 million
EPS: $2.61 per share
Guidance: initiated
Result: reported results

Exact text from the filing

as compared to a net loss of ($12.7) million, or ($1.19) per share, and ($85.4) million, or ($11.41) per share, for the same periods in 2024. ● Commercialization revenues were $120.8 million in 2025 as compared to $128.9 million in 2024. ● Total costs and operating expenses include non-cash stock-based compensation, depreciation and amortization expenses of $1.6

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Atara Biotherapeutics, Inc. reported the fourth quarter ended December 31, 2025 results: net income ($3.4) million, EPS ($0.25) per share. Guidance initiated.

Period: the fourth quarter ended December 31, 2025
Net income: ($3.4) million
EPS: ($0.25) per share
Guidance: initiated
Result: reported results

Exact text from the filing

Atara reported a net loss of ($3.4) million, or ($0.25) per share, and a net income of $32.7 million, or $2.61 per share, for the fourth quarter and fiscal year 2025, respectively

View on SEC.gov

171 earnings releases filed in the last 30 days. Browse all earnings releases →

Atara Biotherapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-108344

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.